Insmed (NASDAQ:INSM) Price Target Raised to $97.00 at Stifel Nicolaus

Insmed (NASDAQ:INSM) had its target price lifted by Stifel Nicolaus from $88.00 to $97.00 in a research report issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would indicate a potential upside of 22.80% from the company’s previous close.

A number of other research analysts also recently issued reports on INSM. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research report on Friday, November 1st. Truist Financial reaffirmed a “buy” rating and issued a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. Guggenheim boosted their price target on shares of Insmed from $95.00 to $101.00 and gave the company a “buy” rating in a report on Friday. Morgan Stanley upped their price target on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $85.60.

Insmed Stock Performance

Shares of NASDAQ INSM traded up $0.87 during trading on Tuesday, reaching $78.99. The stock had a trading volume of 232,328 shares, compared to its average volume of 1,880,366. The firm’s 50 day moving average price is $72.88 and its two-hundred day moving average price is $73.09. Insmed has a one year low of $21.92 and a one year high of $82.04. The stock has a market cap of $14.13 billion, a PE ratio of -14.23 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insider Buying and Selling at Insmed

In other news, insider Martina M.D. Flammer sold 3,344 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the completion of the sale, the insider now directly owns 102,766 shares of the company’s stock, valued at $6,773,307.06. This trade represents a 3.15 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the business’s stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the sale, the insider now directly owns 97,083 shares in the company, valued at $7,766,640. This trade represents a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 401,030 shares of company stock valued at $30,993,629. 4.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Insmed

A number of institutional investors have recently bought and sold shares of INSM. Teacher Retirement System of Texas lifted its position in shares of Insmed by 24.4% in the fourth quarter. Teacher Retirement System of Texas now owns 48,337 shares of the biopharmaceutical company’s stock worth $3,337,000 after purchasing an additional 9,471 shares in the last quarter. Xponance Inc. lifted its position in Insmed by 23.1% in the 4th quarter. Xponance Inc. now owns 12,689 shares of the biopharmaceutical company’s stock worth $876,000 after buying an additional 2,380 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of Insmed by 52.9% during the 4th quarter. Intech Investment Management LLC now owns 71,227 shares of the biopharmaceutical company’s stock valued at $4,918,000 after buying an additional 24,634 shares during the period. William Blair Investment Management LLC grew its holdings in shares of Insmed by 0.5% during the 4th quarter. William Blair Investment Management LLC now owns 2,433,443 shares of the biopharmaceutical company’s stock valued at $168,005,000 after acquiring an additional 12,535 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new position in shares of Insmed in the fourth quarter worth $1,114,000.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.